Hao Shoujiang, Zhang Xiaoying, Qi Xiaojun, Liu Likun, Hao Shulan, Li Xiaoli
Department of Oncology Shanxi Province Hospital of Traditional Chinese Medicine Taiyuan China.
Clin Case Rep. 2025 Aug 4;13(8):e70756. doi: 10.1002/ccr3.70756. eCollection 2025 Aug.
In the contemporary landscape of oncology, immune checkpoint blockade therapy has emerged as a paramount therapeutic modality. However, concomitant with the pervasive deployment of immune checkpoint inhibitors (ICIs), there has been an escalating incidence of adverse drug reactions over the years. Immunological encephalitis, a prevalent form of central nervous system toxicity, poses a significant threat to the lives of affected patients. A 65-year-old male patient, diagnosed with squamous cell carcinoma of the lung, experienced an atypical immune-mediated encephalitis of clinical nature after the administration of a PD-1 inhibitor, specifically Tirelizumab. The present investigation delved into the clinical presentations and suitable therapeutic protocols for immune-mediated encephalitis.
在当代肿瘤学领域，免疫检查点阻断疗法已成为一种至关重要的治疗方式。然而，随着免疫检查点抑制剂（ICIs）的广泛应用，多年来药物不良反应的发生率不断上升。免疫性脑炎是中枢神经系统毒性的一种常见形式，对受影响患者的生命构成重大威胁。一名65岁男性患者，被诊断为肺鳞状细胞癌，在使用PD-1抑制剂替雷利珠单抗后出现了具有临床特征的非典型免疫介导性脑炎。本研究深入探讨了免疫介导性脑炎的临床表现及合适的治疗方案。
